Postherpetic Neuralgia Pipeline and clinical trials Report 2023 Updates: Therapies, Treatment, FDA Approvals, ROA, MOA, Stages of Development and Pipeline Analysis by DelveInsight | Haisco Pharmaceutical Group, Lexicon Pharmaceuticals, Shanghai SIMR Biote

(Las Vegas, Nevada, USA) DelveInsight's "Postherpetic Neuralgia Pipeline Insight, 2023," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Postherpetic Neuralgia pipeline landscape. It covers the Postherpetic Neuralgia pipeline drug profiles, including Postherpetic Neuralgia clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Postherpetic Neuralgia Pipeline Report
• The Postherpetic Neuralgia pipeline report from DelveInsight shows a healthy market with 12+ Companies actively working on 12+ pipeline therapies for the Postherpetic Neuralgia treatment.
• The leading Postherpetic Neuralgia Companies include Haisco Pharmaceutical Group, Lexicon Pharmaceuticals, Shanghai SIMR Biotechnology Co., Ltd., Flexion Therapeutics, Medifron DBT, Oxford Technologies, Acasti Pharma, Clexio Biosciences, Elorac Biotherapeutics, and others.
• Promising Postherpetic Neuralgia Pipeline Therapies include Lidocaine 5% medicated plaster, Pregabalin, HSK16149 20mg BID, HSK16149 40mg BID, Lyrica (pregabalin), DS-5565, pregabalin, Fentanyl, Lidoderm, and others.
• The Postherpetic Neuralgia Companies and academics that are working to assess challenges and seek opportunities that could influence Postherpetic Neuralgia R&D. The Postherpetic Neuralgia pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

Request a sample and discover the recent advances in Postherpetic Neuralgia Drug Treatment @ Postherpetic Neuralgia Pipeline Report- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Postherpetic Neuralgia Overview
Post-herpetic neuralgia is defined as a chronic neuropathic pain that persists for three or more months following acute Herpes zoster (shingles) infection. It is a severe painful secondary phase, which may develop three to six months after the resolution of initial phase of Herpes zoster (HZ) infection. Pain has a dermatomal distribution and is confined to same dermatome as the rash.
The neuralgia is excruciating with superimposed lancinating paresthesias. Pain may be constant or intermittent, aggravated by minor stimulus (allodynia) such as heat or touch, and is worse at night. The agony of pain leads to insomnia, anorexia, and changes in mood (severe depression)

Recent Developmental Activities in the Postherpetic Neuralgia Treatment Landscape

• LX9211 and another development candidate were discovered by scientists working within Lexicon's drug discovery alliance with Bristol-Myers Squibb from which Lexicon hold exclusive development and commercialization rights. Currently, it is in Phase II stage of clinical trial evaluation to treat Postherpetic Neuralgia.

Find out more information of the latest Postherpetic Neuralgia Drugs Launch, News, and Breakthroughs of the Postherpetic Neuralgia Pipeline Report @ Latest Postherpetic Neuralgia Drugs Launch- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Postherpetic Neuralgia Drugs Profile

• HSK16149: Haisco Pharmaceutical Group
HSK16149 is being developed by Haisco Pharmaceutical Group to treat Postherpetic Neuralgia. The company is currently conducting a multicenter, randomized, double-blind, placebo-controlled, 12-week, Phase III study to evaluate the efficacy and safety of HSK16149 capsules in chinease patients with Postherpetic Neuralgia.

• LX9211: Lexicon Pharmaceuticals
LX9211 is an orally-delivered small molecule compound that we are developing as a treatment for neuropathic pain. Scientists identified the target of LX9211, adapter-associated kinase 1, or AAK1, in a target discovery efforts based on their discovery that mice lacking AAK1 exhibited increased resistance to induced neuropathic pain in preclinical models.

Postherpetic Neuralgia Pipeline Therapeutics Assessment

There are approx. 12+ key Postherpetic Neuralgia companies which are developing the therapies for Postherpetic Neuralgia patients. The companies which have their Postherpetic Neuralgia drug candidates in the most advanced stage, i.e. phase III include, Haisco Pharmaceutical Group.

Learn more about the emerging Postherpetic Neuralgia pipeline therapies @ Postherpetic Neuralgia Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Postherpetic Neuralgia Pipeline Report

• Coverage- Global

• Postherpetic Neuralgia Companies- Haisco Pharmaceutical Group, Lexicon Pharmaceuticals, Shanghai SIMR Biotechnology Co., Ltd., Flexion Therapeutics, Medifron DBT, Oxford Technologies, Acasti Pharma, Clexio Biosciences, Elorac Biotherapeutics, and others.

• Postherpetic Neuralgia drugs- Lidocaine 5% medicated plaster, Pregabalin, HSK16149 20mg BID, HSK16149 40mg BID, Lyrica (pregabalin), DS-5565, pregabalin, Fentanyl, Lidoderm, and others.

• Postherpetic Neuralgia Pipeline Segmentation- Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Postherpetic Neuralgia Market Drivers and Postherpetic Neuralgia Market Barriers, click here @ Postherpetic Neuralgia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Postherpetic Neuralgia: Overview
4. Postherpetic Neuralgia Pipeline Therapeutics
5. Postherpetic Neuralgia Therapeutic Assessment
6. Postherpetic Neuralgia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. HSK16149: Haisco Pharmaceutical Group
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. LX9211: Lexicon Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. AAT 730: Oxford Technologies
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Postherpetic Neuralgia Key Companies
21. Postherpetic Neuralgia Key Products
22. Postherpetic Neuralgia- Unmet Needs
23. Postherpetic Neuralgia- Market Drivers and Barriers
24. Postherpetic Neuralgia- Future Perspectives and Conclusion
25. Postherpetic Neuralgia Analyst Views
26. Postherpetic Neuralgia Key Companies
27. Appendix

Got Queries? Find out the related information on Postherpetic Neuralgia Mergers and acquisitions, Postherpetic Neuralgia Licensing Activities @ Postherpetic Neuralgia Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/postherpetic-neuralgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Menorrhalgia Market - https://www.delveinsight.com/report-store/menorrhalgia-market
• Complicated Intra-Abdominal Infections market - https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market
• Bronchial Spasm Market - https://www.delveinsight.com/report-store/bronchial-spasm-market
• Acute Radiation Syndrome Market - https://www.delveinsight.com/report-store/acute-radiation-syndrome-market
• Age Related Vision Dysfunction Market - https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market
• Cerebral Aneurysm Market - https://www.delveinsight.com/report-store/cerebral-aneurysm-market
• Severe Hypoglycemia Market - https://www.delveinsight.com/report-store/severe-hypoglycemia-market
• Ada-Scid Competitive Landscape - https://www.delveinsight.com/report-store/ada-scid-competitive-landscape-and-market-insight
• DCSSC Market - https://www.delveinsight.com/report-store/diffuse-cutaneous-systemic-sclerosis-dcssc-market

Contact Us:
Ankit Nigam
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.